Enanta Pharmaceuticals | ENTA - Gross Profit On Sales


Enanta Pharmaceuticals reported -22.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 73.74M 190.3M Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Immunic 0 0 Mar/2025
Incyte USD 1.57B 400.89M Jun/2026
Insmed USD 356.19M 99.73M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026